Did you mean 410 50 0?
Displaying drugs 1726 - 1750 of 2654 in total
XTL-001
XTL001 is an investigational monoclonal antibody (MAb) product developed by XTL Biopharmaceuticals to evaluate the safety profile and antiviral activity of the compound in patients chronically infected with hepatitis B virus (HBV).
Investigational
AGS-005
AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's cancer cells.
Investigational
NV-07a
NV-07a is topical skin repair compound protecting skin from sun-induced immunosuppression and UV-induced damage.
Investigational
MK-0354
MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.
Investigational
GS 0573
Investigational
HT-0712
BLX-028914 has been used in trials studying the treatment and basic science of Allergic Rhinitis and Age-Associated Memory Impairment (AAMI).
Investigational
MK-0812
MK0812 has been used in trials studying the treatment of Relapsing-Remitting Multiple Sclerosis.
Investigational
MK-0893
MK0893 has been used in trials studying the treatment of Type 2 Diabetes Mellitus and Diabetes Mellitus, Type 2.
Investigational
MK-0767
MK0767 has been used in trials studying the treatment of Dyslipidemia, Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, and Diabetes Mellitus, Type II, among others.
Investigational
RRx-001
RRx-001 has been used in trials studying the treatment of Lymphomas, Brain Metastases, Cholangiocarcinoma, Colorectal Neoplasms, and Malignant Solid Tumor, among others.
Investigational
ATU-027
Atu027 has been used in trials studying the treatment of Advanced Solid Tumors.
Investigational
MK-0873
MK-0873 has been used in trials studying the treatment of Rheumatoid Arthritis.
Investigational
ONT-093
ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics.
Investigational
TMV-083
TMV-083 is an attenuated live virus COVID-19 vaccine candidate which employs the measles vaccine as a vector . It expresses a spike protein antigen from SARS-CoV-2 .
Investigational
ANX-005
Investigational
MRK-003
MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of MK-0752, a drug in clinical development.
Investigational
SYD-003
Investigational
MV-NB-02
Investigational
MRG-003
MRG-003 is a recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated to monomethyl auristatin E.
Investigational
ACP-015
Investigational
SIG-001
SIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer modified alginate spheres.
Investigational
RST-001
RST-001 is a non-replicating recombinant adeno-associated virus vector containing a fragment of the gene encoding channel rhodopsin-2 protein.
Investigational
NBL-015
Investigational
FCX-013
FCX-013 consists of human dermal fibroblasts genetically modified with a lentiviral vector expressing metalloproteinase-1 (MMP-1).
Investigational
Displaying drugs 1726 - 1750 of 2654 in total